#United States #New York #Novellia #Healthcare Data #Patient Empowerment

Novellia's Major Funding Round Empowers Patient-Centric Data Solutions

In a groundbreaking move for the healthcare sector, Novellia, a pioneering company focused on patient-powered data, has successfully secured $18 million in Series A funding. This significant investment, led by Spark Capital with participation from prominent venture firms such as Khosla Ventures and Acrew Capital, boosts Novellia’s total funding to $28 million. The company, headquartered in New York, is on a mission to revolutionize medical research by placing patients at the forefront of data collection.

As the demand for real-world data in pharmaceutical research continues to grow, Novellia aims to fill a critical gap in the industry. Traditional methods have relied heavily on incomplete datasets derived from insurance claims and hospital records, which often fail to represent the full patient experience. Shashi Shankar, co-founder and CEO of Novellia, articulated the issue, highlighting how many patients have fragmented records that do not capture their entire medical journeys.

“In my personal experiences and professional observations, I recognized that the system was inadequate,” said Shankar. “We often developed drugs without understanding the complete picture of patient needs. With Novellia, we aim to change this narrative by empowering patients and researchers equally.”

The recent funding will propel Novellia's advanced AI-driven technology that enables patients to access and organize up to 20 years of their medical history securely. This innovative platform allows users to control their data while facilitating crucial contributions to medical research. A significant feature is the newly launched patient-facing mobile app, which extends the award-winning capabilities of its online platform.

With its AI technology, Novellia consolidates fragmented health records from various providers into a single comprehensive and user-friendly source. Additionally, the app ensures that patients can share their anonymized data with leading pharmaceutical companies, unlocking insights that can lead to groundbreaking therapies and advancements.

Alex Finkelstein, General Partner at Spark Capital, acknowledged the need for such a solution, stating the pharmaceutical industry has long struggled with outdated and uncoordinated patient data. He emphasized the significance of Novellia's approach, which bridges the gap between patient willingness to share information and the current infrastructure existing in medical research.

Notably, about 70% of patients expressed openness to sharing their health data for scientific progress, given they are assured control, transparency, and privacy capabilities. Novellia’s model directly addresses these concerns, making it a vital player in the future of health data management.

The platform's technology utilizes natural language processing (NLP) to analyze unstructured clinical text, extracting valuable information from physician notes and diagnostic reports. This often-overlooked layer of medical records contains insights that can significantly enhance research quality and inform clinical decisions.

Named one of Digital Health New York's startups to watch, and a recipient of the 2026 Fierce Outsourcing Award for innovation in drug development, Novellia is quickly establishing itself as a critical competitor in the healthcare data industry. The continued success in securing major pharmaceutical contracts showcases Novellia's potential to reshape the landscape of medical research and patient care.

For more information on Novellia and its innovative solutions, visit Novellia’s website.